Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
about
NMDA receptor modulators: an updated patent review (2013-2014)Study protocol of a randomised controlled trial of intranasal ketamine compared with intranasal fentanyl for analgesia in children with suspected, isolated extremity fractures in the paediatric emergency department.Resurfacing of ketamine: The subanesthetic paradigm.Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.Clinically Relevant Concentrations of Ketamine Inhibit Osteoclast Formation In Vitro in Mouse Bone Marrow Cultures.Sickle cell pain management: are we missing the role of pronociception and neuropathic pain?
P2860
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Low-dose ketamine as a potenti ...... crises in sickle cell disease.
@en
type
label
Low-dose ketamine as a potenti ...... crises in sickle cell disease.
@en
prefLabel
Low-dose ketamine as a potenti ...... crises in sickle cell disease.
@en
P2093
P2860
P356
P1476
Low-dose ketamine as a potenti ...... crises in sickle cell disease.
@en
P2093
Caitlin M Neri
Deepika S Darbari
Sophie R Pestieau
P2860
P304
P356
10.1111/PAN.12172
P577
2013-04-09T00:00:00Z